As of October 31, the company had cash, cash equivalents and marketable securities of approximately $135.8M, or $292.2M, on a pro forma basis, including $156.4M net proceeds raised in November. The company anticipates that this pro forma balance provides sufficient runway into the second half of 2027. “KalVista (KALV) is successfully executing on the key milestones we announced at the beginning of our fiscal year as we move towards multiple potential commercial launches of sebetralstat in 2025,” said CEO Ben Palleiko. “With six marketing authorization applications filed to date and the first potential approval expected next June, we remain focused on achieving our goal of making sebetralstat available to people living with HAE globally. In support of that goal, during the quarter, we presented additional data from our clinical program at multiple conferences, demonstrating that patients used sebetralstat to treat attacks early and that early treatment with on-demand therapy resulted in meaningful clinical benefit. Finally, the additional capital we recently raised, including the non-dilutive synthetic royalty financing, will support our continued planning for the potential launch of sebetralstat in multiple markets.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KALV:
- Is KALV a Buy, Before Earnings?
- KalVista Pharmaceuticals Appoints Laurence Reid to Board
- KalVista Pharmaceuticals Announces $60 Million Funding Initiatives
- KalVista enters synthetic royalty financing with DRI Healthcare Trust
- KalVista Secures $184M Financing for Sebetralstat Launch
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
